Navigation Links
Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
Date:8/8/2011

continuing the dispute resolution process because we strongly believe that there is a patient population for Contrave that has a risk:benefit profile that justifies approval without results from a cardiovascular outcomes trial," stated Mike Narachi, Orexigen President and CEO.  "Importantly, we have prioritized the pursuit of additional assets and are optimistic in these business development efforts."  

About Orexigen TherapeuticsWe are a biopharmaceutical company focused on expanding our pipeline of product candidates through one or more in-license, asset acquisitions or merger transactions where we can leverage our management team, cash and other resources.  Our strategy stems from feedback received from the U.S. Food and Drug Administration, or FDA, concerning substantial additional development requirements for our lead product candidate, Contrave.  Contrave has completed Phase III clinical trials, and our other product candidate, Empatic™, has completed Phase II clinical trials.  Each of the components of our product candidates has already received regulatory approval and has been commercialized previously.  We are appealing the FDA's additional development requirements for Contrave through the formal dispute resolution process. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements  Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.  Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the Company's current beliefs and expectations.  These forward-looking statements include statements regarding substantially lower c
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... Va. , Jan. 14, 2014 Animal Emergency Critical Care, ... Leesburg, Virginia is the first in ... oxygen chamber. Dr. Susan M. Barnes , ... Dr. Barnes and husband, Dr. Cole Taylor , are avid ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... launched ABAS ( Atlas-based Autosegmentation ) 2.0 software, ... Estimation (STAPLE) algorithm to increase contouring accuracy. ABAS—considered ... of anatomy previously defined on a reference image ... structure set fit to the patient anatomy and ...
... Pa., Oct. 1 Encorium Group, Inc. (Nasdaq: ... conducting studies in over 30 countries for many of the ... has extended the expiration date for its pending rights offering ... rights may now be exercised at any time prior to ...
Cached Medicine Technology:Elekta Launches ABAS 2.0 Autosegmentation Software Used to Plan Radiation Therapy in Patients With Cancer 2Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 2Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 3Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 4Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 5Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering 6
(Date:4/23/2014)... MD (April 23, 2014) The American Gastroenterological ... the 2014 AGA Research Scholars. The AGA Research ... investigators to develop independent and productive research careers ... Scholar Awards fund an additional year allowing for ... committed to supporting junior faculty who are paving ...
(Date:4/23/2014)... in the popular Swedish children,s TV show Bolibompa, ... A new study from the University of Gothenburg ... programmes as well as the link between young ... , Steingerdur Olafsdottir,s doctoral thesis focuses on the ... TV show Bolibompa. Healthy foods dominated in the ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington ... Proof of Concept grants to accelerate maturation of ... the Life Sciences Discovery Fund (LSDF) announced today. ... grant to the Washington Biotechnology & Biomedical Association ... train the next generation of entrepreneurs and help ...
(Date:4/23/2014)... an increase in adolescents, marijuana use following the legalization ... According to a new study at Rhode Island Hospital ... with and without medical marijuana laws, legalizing the drug ... study is published online in advance of print in ... "Any time a state considers legalizing medical marijuana, there ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
Breaking Medicine News(10 mins):Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... Health Magazine, SEATTLE, June 5 Kagome, one ... Mango Orchard natural 100 percent juice,blend have been named ... With the help of top health experts, Health ... fitness to the ultimate test,and unveiled a total of ...
... influences fat metabolism , , THURSDAY, June 5 (HealthDay News) ... truism familiar to the diet-conscious choosing between carrots and ... isn,t just a matter of what you put in ... genetically predisposed to process fat. , The theory is ...
... The U. S. Army Corps of,Engineers, in partnership ... and recreation industry partners, will,participate in the first ... On this day, more than 75 organizations will ... privately-managed recreation sites,across the country according to event ...
... veterinarians perform leading-edge techniques and,identify animal research ... both,horses and humans, WASHINGTON, June 5 ... releases its feature film Majestic starring some,of ... Bramlage (Rood & Riddle,Equine Hospital) and Dr. ...
... naturally occurring fat molecule have the potential to slow ... researchers report. , Through both the normal aging ... skin inevitably becomes coarse and wrinkled. The basis of ... the production of new collagen while increasing the levels ...
... percent of patients who recently underwent liver transplantation ... factors included having had biliary-enteric anastomosis (choledocho-jejunal or ... more than four red blood cell units transfused. ... of Liver Transplantation, a journal by John Wiley ...
Cached Medicine News:Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 2Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 3Health News:Weight Gain May Not Be Based Just on What You Eat 2Health News:Weight Gain May Not Be Based Just on What You Eat 3Health News:Army Corps of Engineers Will Host National Get Outdoors Day Activities at Six Corps Project Sites 2Health News:The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere 2Health News:Researchers determine risk factors for infection after liver transplantation 2
... for High Throughput Screening (HTS), Analyst ... into HTS by sharing all the ... Analyst AD, fluorescence intensity, fluorescence plarization, ... for seamless integration into robotic environments, ...
... most advanced multi-functional microplate detection system, ... performance without compromising flexibility. ,The ... on the Ultra instrument platform. New ... adds to the flexibility of the ...
... The FLUOstar is a flexible multifunction ... modes in one instrument: fluorescence intensity, time-resolved ... OPTIMA can be equipped with injectors that ... so that fast kinetic cell assays can ...
The basic modular Wallac 1420 VICTOR2 is a manually operated platereader which enables luminometry, fluorometry and photometry measurements to be made....
Medicine Products: